We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microbiota’s Role Explored in Colorectal Cancer Among the Young

By LabMedica International staff writers
Posted on 06 Feb 2020
Colorectal cancer incidence has been declining for several decades in people over 55, in part because of the increased use of screening for the disease, particularly with colonoscopy which can find and remove polyps before they become cancerous.

However such screenings are generally not recommended for people under age 50, but colorectal cancer rates have been increasing at nearly a 2% annual rate in people under age 55 since 2006. More...
There are many theories about why, including a rise in obesity, diabetes, and diets low in whole grains among younger people.

Bacteria typically linked to periodontal disease, Fusobacterium nucleatum, could play an important role in the rising incidence of colorectal cancer in people under the age of 45. Another type of bacteria, Moraxella osloensis, has been found in colorectal cancer tumors at a nearly four-fold higher rate in people over 75 than in those under 45 years of age, pointing out how differences in the bacteria that comprise what is known as the body's microbiome could affect cancer outcomes to varying degrees.

Oncologists at the Georgetown Lombardi Comprehensive Cancer Center (Washington, DC, USA) analyzed the role of the microbiome in colorectal cancer. To do this they looked at the DNA and microbiome of archived tumors, as well as adjacent normal tissue when available, from 31 patients with colorectal cancer who were diagnosed before the age of 45 or after the age of 65.

Scientists have known that certain microbes that comprise the microbiome, which consists of different types of bacteria, fungi and viruses, can disturb the lining of the colon and promote tissue inflammation. This can result in mutations to the DNA of cells in the colon and lead to cancer. Scientists also know that F. nucleatum can promote cancerous growth by suppressing immune responses in the colon.

Overall, the investigators found 478 unique bacterial and fungal species in the tumors. One of the most common bacteria found was F. nucleatum, which appeared in five of the younger patients' tumors and in three of the older patients' tumors. The team also found a significant difference in the rate of Moraxella osloensis (11% versus 46%) in younger compared to older patients.

Benjamin Adam Weinberg, MD, an assistant professor of medicine and a senior author of the study, said, “There was a much higher presence of F. nucleatum in younger patients than we expected. We haven't seen large genetic differences in colorectal tumors from younger versus older people, so we hypothesize that something else, perhaps the microbiome, is contributing to the rise in incidence of the disease in younger people.” The study was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium held January 23-25, 2020 in San Francisco, CA, USA).

Related Links:
Georgetown Lombardi Comprehensive Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.